BioCatalystWatch
CVKDWorkspace / CVKD / OverviewCompany library
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. (CVKD)

Website

Price
Market cap
Next catalystPlanned later in 2026, subject to sufficient funding to complete the trialCAD-1005 — planned Phase 2a CSA-AKI study · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

Frunexian

Factor XIa

PreINDP1P2P3FilingApproved
CAD-1005

12-LOX

PreINDP1P3FilingApproved
Upcoming / outlook

Tecarfarin

Vitamin K

PreINDP1P2P3FilingApproved
Tecarfarin

CAD-2000

12-LOX

PreINDP1P2P3FilingApproved

History / paused

CAD-1005

12-LOX

PreINDP1P2P3FilingApproved
CAD-1005

12-LOX

PreINDP1P2FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

CVKD PR & News

PR & News

CVKD SEC archive